- Welcome & Introduction
- Biomarker Testing for EGFR Mutation Status in Newly Diagnosed NSCLC
- Tissue-based vs blood-based testing
- Interpreting results to individualize therapy selection
- Selecting First-line Therapy in EGFR Mutation–Positive Advanced/Metastatic NSCLC
- Implications on therapy choice of most recent phase III trial data and use of adjuvant EGFR TKI therapy for early-stage disease
- Examining first-line EGFR TKI–based combination therapy
- Considerations for special patient populations
- Acquired Resistance Following Prior EGFR TKI Therapy
- Mechanisms of resistance to available EGFR TKIs
- Considerations for Specialty Pharmacy
- Audience Question & Answer Session
Date / Time
Stefanie Houseknecht, PharmD, BCOP
Clinical Pharmacy Specialist
The Johns Hopkins Hospital and Bayview Medical Center
The goal of this activity is to improve the knowledge, competence, and performance of learners to optimally integrate current data needed to make treatment decisions and improve outcomes in the EGFR mutation–positive NSCLC patient population.
This program is intended for physicians, nurses, pharmacists, and other healthcare providers who care for patients with EGFR mutation–positive NSCLC.
Upon completion of this activity, participants should be able to:
- Implement best practices and guideline-endorsed molecular testing algorithms in NSCLC for evaluation of EGFR mutation status in newly diagnosed patients and those with acquired resistance following EGFR TKI therapy
- Compare available efficacy and safety data of systemic therapies throughout the continuum of EGFR mutation–positive metastatic or locally advanced NSCLC from the first-line setting to the second-line setting and beyond (including outcomes by type of EGFR mutation and the presence of co-mutations)
- Describe the biologic rationale for the design of clinical trials combining EGFR-targeted and VEGFR-targeted therapy in EGFR mutation–positive NSCLC and potential ramifications for practice based on recent clinical trial results
- Plan therapy based on an understanding of the subtype of EGFR mutation as well as co-mutations such as TP53
- Refine EGFR mutation–positive metastatic and locally advanced NSCLC treatment algorithms based on molecular profile and prior therapy exposure in earlier lines of therapy
- Identify patients eligible to enroll on important ongoing clinical trials evaluating promising investigational agents and combinations for EGFR mutation–positive NSCLC
Joint Accreditation Statement
In support of improving patient care, this activity has been planned and implemented by Clinical Care Options, LLC (CCO) and ProCE, LLC. Clinical Care Options, LLC (CCO) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC) to provide continuing education for the healthcare team.
Physician Continuing Medical Education
Designation of Credit
CCO designates this live activity for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Nursing Continuing Education
The maximum number of hours awarded for this Continuing Nursing Education activity is 1.0 contact hour.
Continuing Pharmacy Education
CCO designates this continuing education activity for 1.0 contact hour (0.1 CEUs) of the Accreditation Council for Pharmacy Education. Universal Activity Number - JA4008176-9999-22-204-L01-P
Type of Activity: Application
Upon successfully completing the activity evaluation form, transcript information will be sent to the NABP CPE Monitor Service within 60 days.
Disclosure of Conflicts of Interest
Clinical Care Options, LLC (CCO) and ProCE, LLC require instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose all financial conflicts of interest (COI) they may have with ineligible companies. All relevant COI are thoroughly vetted and mitigated according to CCO and ProCE policy. CCO and ProCE are committed to providing its learners with high-quality CME/CE activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of an ineligible company.